AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Cell cycle checkpoint protein RAD1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

O60671

UPID:

RAD1_HUMAN

Alternative names:

DNA repair exonuclease rad1 homolog; Rad1-like DNA damage checkpoint protein

Alternative UPACC:

O60671; O75572; O95304; Q1W161; Q5KSM0; Q5KSM1; Q9UEP1

Background:

Cell cycle checkpoint protein RAD1, also known as DNA repair exonuclease rad1 homolog and Rad1-like DNA damage checkpoint protein, is a key component of the 9-1-1 cell-cycle checkpoint response complex. This complex plays a pivotal role in DNA repair, being recruited to DNA lesions upon damage. It acts as a sliding clamp platform for several proteins involved in long-patch base excision repair (LP-BER), thereby facilitating DNA polymerase beta activity, endonuclease FEN1 cleavage activity, and DNA ligase I activity on repair substrates.

Therapeutic significance:

Understanding the role of Cell cycle checkpoint protein RAD1 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.